Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results

Liotti, Flora Marzia; Menchinelli, Giulia; Marchetti, Simona; Posteraro, Brunella; Landi, Francesco; Sanguinetti, Maurizio; Cattani, Paola

doi:10.1001/jamainternmed.2020.7570

Cited by 52 publications

(51 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the substantial number of infants who received iv antibiotics until the exclusion of bacterial co-infection justifies the increasing concern of a possible negative impact of the virus on antibiotic stewardship. Interestingly, in contrast to what has been reported for older children with COVID-19 [13], 5 infants had positive PCR for more than 3 weeks although with high Ct values which was suggestive that the virus was not transmissible [14].…”

Section: Table 1 Epidemiological and Clinical Characteristics Of Infacontrasting

confidence: 80%

Clinical characteristics of COVID-19 in neonates and young infants

et al. 2021

View full text Add to dashboard Cite

We report the clinical characteristics and management of fourteen neonates and very young infants with COVID-19. Although all presented with mild symptoms and did not require specific treatment, most of them had abnormal laboratory and radiological findings. Ten infants presented with neutropenia and/or monocytosis but none with lymphopenia. Transient hypertriglyceridemia and/or prolonged viral shedding were detected in 9 patients.Conclusion: Based to our experience, COVID-19 is mild in very young infants and might have distinct laboratory findings. Keywords COVID-19 . Infants . SARS-CoV-2 . Pandemic Abbreviations BPD Bronchopulmonary dysplasia RT-PCR Real-time reverse transcriptase polymerase chain reaction SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Communicated by Nicole Ritz

show abstract

Section: Table 1 Epidemiological and Clinical Characteristics Of Infacontrasting

confidence: 80%

Clinical characteristics of COVID-19 in neonates and young infants

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This absence of the full-spectrum of COVID-19-related complications in this study is likely multifactorial. First, many of the COVID patients likely recovered from previous COVID or had only mild infection, which is supported by our low rates of COVID-19-related symptoms and imaging findings [22,23]. Second, the low ISS scores in our study indicate that a large portion of our COVID cohort sustained minor trauma which perhaps is not a powerful enough insult to trigger COVID-19 complications.…”

Section: Discussionsupporting

confidence: 58%

COVID-19 in trauma: a propensity-matched analysis of COVID and non-COVID trauma patients

Yeates

Grigorian

Schellenberg

et al. 2021

Eur J Trauma Emerg Surg

View full text Add to dashboard Cite

Purpose There is mounting evidence that surgical patients with COVID-19 have higher morbidity and mortality than patients without COVID-19. Infection is prevalent amongst the trauma population, but any effect of COVID-19 on trauma patients is unknown. We aimed to evaluate the effect of COVID-19 on a trauma population, hypothesizing increased mortality and pulmonary complications for COVID-19-positive (COVID) trauma patients compared to propensity-matched COVID-19-negative (non-COVID) patients. Methods A retrospective analysis of trauma patients presenting to 11 Level-I and II trauma centers in California between 1/1/2019–6/30/2019 and 1/1/2020–6/30/2020 was performed. A 1:2 propensity score model was used to match COVID to non-COVID trauma patients using age, blunt/penetrating mechanism, injury severity score, Glasgow Coma Scale score, systolic blood pressure, respiratory rate, and heart rate. Outcomes were compared between the two groups. Results A total of 20,448 trauma patients were identified during the study period. 53 COVID trauma patients were matched with 106 non-COVID trauma patients. COVID patients had higher rates of mortality (9.4% vs 1.9%, p = 0.029) and pneumonia (7.5% vs. 0.0%, p = 0.011), as well as a longer mean length of stay (LOS) (7.47 vs 3.28 days, p < 0.001) and intensive care unit LOS (1.40 vs 0.80 days, p = 0.008), compared to non-COVID patients. Conclusion This multicenter retrospective study found increased rates of mortality and pneumonia, as well as a longer LOS, for COVID trauma patients compared to a propensity-matched cohort of non-COVID patients. Further studies are warranted to validate these findings and to elucidate the underlying pathways responsible for higher mortality in COVID trauma patients.

show abstract

“…Recent studies showed Ag-RDT is unable to detect SARS-CoV-2 at a Ct value of more than 19 [ 22 ]. Other reports have revealed the diagnostic sensitivity of Ag-RDT to be 95% at Ct values < 25 but declines drastically to 20–40% when the Ct value is > 25 [ 23 ]. In contrast to all these observations, the GenBody TM COVID-19 Ag test COVAG025 showed diagnostic sensitivities of 90–100% at Ct levels ≤ 25 in residual samples and unconfirmed fresh samples, which also further persisted at Ct levels > 25.…”

Section: Discussionmentioning

confidence: 99%

Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody™ COVAG025) for COVID-19 Diagnosis

Kim

Lee

Bal

et al. 2021

Viruses

View full text Add to dashboard Cite

Antigen tests for SARS-CoV-2 diagnosis are simpler and faster than their molecular counterparts. Clinical validation of such tests is a prerequisite before their field applications. We developed and clinically evaluated an immunochromatographic immunoassay, GenBody™ COVAG025, for the rapid detection of SARS-CoV-2 nucleocapsid (NP) antigen in two different clinical studies. Retrospectively, 130 residual nasopharyngeal swabs transferred in viral transport medium (VTM), pre-examined for COVID-19 through emergency use authorization (EUA)-approved real-time RT-PCR assay and tested with GenBody™ COVAG025, revealed a sensitivity and specificity of 90.00% (27/30; 95% CI: 73.47% to 97.89%) and 98.00% (98/100; 95% CI: 92.96% to 99.76%), respectively, fulfilling WHO guidelines. Subsequently, the prospective examination of 200 symptomatic and asymptomatic nasopharyngeal swabs, collected on site and tested with GenBody™ COVAG025 and EUA-approved real-time RT-PCR assay simultaneously, revealed a significantly higher sensitivity and specificity of 94.00% (94/100; 95% CI: 87.40% to 97.77%) and 100.00% (100/100; 95% CI: 96.38% to 100.00%), respectively. Clinical sensitivity and specificity were significantly high for samples with Ct values ≤ 30 as well as within 3 days of symptom onset, justifying its dependency on the viral load. Thus, it is assumed this can help with the accurate diagnosis and timely isolation and treatment of patients with COVID-19, contributing to better control of the global pandemic.

show abstract

Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results

Abstract: The data are publicly available. Analysis code for replication is provided via the weblink in the main text.

Cited by 52 publications

References 5 publications

Clinical characteristics of COVID-19 in neonates and young infants

Clinical characteristics of COVID-19 in neonates and young infants

COVID-19 in trauma: a propensity-matched analysis of COVID and non-COVID trauma patients

Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody™ COVAG025) for COVID-19 Diagnosis

Contact Info

Product

Resources

About